Anx-131 Official

In chronic stress and PTSD, the brain doesn't need more inhibition; it needs to restore normal phasic inhibition. Current theories suggest that in anxiety disorders, extrasynaptic receptors (δ-subunit containing) become hyperactive, leading to a "tonic" (constant) inhibitory noise that actually destabilizes neural networks.

For decades, the treatment of Generalized Anxiety Disorder (GAD) and post-traumatic stress disorder (PTSD) has been a pharmacological balancing act. On one side, you have benzodiazepines (Xanax, Valium)—effective but highly addictive, with tolerance and withdrawal risks. On the other, you have SSRIs (Zoloft, Prozac)—safe but slow-acting, with side effects that often make patients quit before they work.

Wait—a negative modulator for anxiety ? That sounds backwards. Here is the clever biophysics: The GABA-A receptor has many subunits. ANX-131 is highly selective for the α4β3δ subunit. ANX-131

Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch.

If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s. In chronic stress and PTSD, the brain doesn't

But what if there was a third path? Enter , a novel, oral, negative allosteric modulator (NAM) of the GABAA receptor.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. ANX-131 is an investigational drug that has not been approved by the FDA or other global regulatory bodies. By [Your Name/Handle] That sounds backwards

ANX-131 is a . It gently reduces the overactive tonic current caused by these δ-subunits, allowing the brain’s natural phasic (on-demand) inhibition (via α1 and α2 subunits) to work properly again.